Loading...
•
Jul 02, 2022
Bioventus Q2 2022 Earnings Report
Reported strong growth, driven by acquisitions and organic business expansion.
Key Takeaways
Bioventus reported a net sales increase of 27.8% year-over-year to $140.3 million in Q2 2022. The company's net loss improved to ($8.0) million, and adjusted EBITDA increased to $22.9 million. The company updated its full-year 2022 financial guidance.
Net Sales of $140.3 million, up 27.8% year-over-year as reported.
Net Loss of ($8.0) million, compared to ($10.8) million in prior-year period.
Adjusted EBITDA of $22.9 million, compared to $19.9 million in prior-year period.
Non-GAAP earnings per share of Class A common stock of $0.10, compared to $0.11 in prior-year period.
Revenue by Geographic Location
Forward Guidance
Bioventus updated its full year 2022 financial guidance, expecting net sales of $547.5 million to $562.5 million and adjusted EBITDA of $94 million to $104 million. It also introduced Non-GAAP EPS guidance of $0.47 to $0.57.
Positive Outlook
- Net sales of $547.5 million to $562.5 million, representing year-over-year growth of approximately 27% to 31%.
- Adjusted EBITDA of $94 million to $104 million, compared to $80.8 million for the year ended December 31, 2021.
- Non-GAAP EPS of $0.47 to $0.57, compared to $0.75 for the year ended December 31, 2021.
- The company is now providing Non-GAAP EPS guidance in light of the completion of the CartiHeal acquisition on July 12, 2022.
- Guidance reflects management's current expectations regarding the impact of COVID-19 on its business.
Challenges Ahead
- Adjusted EBITDA guidance update from the prior guidance of $94 million to $107 million due to the inclusion of expenses related to CartiHeal.
- COVID-19 pandemic could cause the Company’s future operating results to be different from current expectations, particularly if the impact of the pandemic worsens.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...